Actively Recruiting
Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients with Type 1 Diabetes (T1D)
Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2024-11-22
25
Participants Needed
1
Research Sites
159 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this randomized crossover study is to test the prediction that consuming carbohydrates will affect insulin release differently depending on whether Non-Nutritive Sweeteners (NNSs) are consumed simultaneously. We aim to determine whether the predicted effects are associated with oral or post-oral sweet taste receptor signaling,. Our study will focus on patients diagnosed with type 1 diabetes (T1D) who are using an artificial pancreas (AP) system, as it allows us to monitor glucose and insulin levels over time. Participants will drink four different flavored beverages, some with sweet taste blockade and some without, in a counter-balanced order. They will then rate the sweetness of each beverage, and we will collect data from their AP system to monitor insulin and glucose level. To achieve this, we will conduct a pilot study to assess the effectiveness and best timing of sweet taste blockade in healthy individuals. Insights gained from the pilot study will inform the main study. Sucralose will be used as the NNS, maltodextrin as the carbohydrate, and Gymnema Sylvestre (GS) as the sweet taste receptor blocker.
CONDITIONS
Official Title
Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients with Type 1 Diabetes (T1D)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with type 1 diabetes
- HbA1C level less than or equal to 8%
- Using insulin pump therapy
- Adults aged 18 to 45 years
- Body Mass Index (BMI) between 18.5 and 29.9 kg/m²
- Non-smokers
- Able to speak English or French
- Can consume chicken and fish
You will not qualify if you...
- Having a major medical condition other than type 1 diabetes that affects metabolism
- Alcohol or substance use disorder
- Eating disorder or history of malabsorption
- Inflammatory bowel disease
- Impaired taste or smell
- Known taste or smell dysfunction such as anosmia
- Currently pregnant or breastfeeding
- Food allergies or intolerances
- Dislike of the test beverages
- History of bariatric surgery
- Regular use of Gymnema sylvestre
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center for Innovative Medicine, The Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
Research Team
G
Golnaz Arjmand, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here